Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 5/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22990194 | 1.00 | OPRM1 (0.33) | OPRM1OPRD1OPRK1OPRL1CHRM2 | |
| SCHEMBL22990416 | 1.00 | OPRM1 (0.33) | OPRM1OPRD1OPRK1OPRL1CHRM2 | |
| SCHEMBL22990202 | 0.85 | OPRM1 (0.32) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL24425054 | 0.85 | OPRM1 (0.32) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL22990197 | 0.85 | OPRM1 (0.36) | OPRM1OPRD1OPRK1OPRL1CYP2D6 | |
| SCHEMBL22962267 | 0.85 | OPRM1 (0.36) | OPRM1OPRD1OPRK1OPRL1CYP2D6 | |
| SCHEMBL22990198 | 0.82 | S1PR1 (0.34) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL24425028 | 0.82 | S1PR1 (0.34) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL24425026 | 0.82 | S1PR1 (0.34) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL22962175 | 0.80 | OPRM1 (0.36) | OPRM1OPRD1OPRK1OPRL1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220144802-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144802-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | SSTR5, SSTR4, SSTR3 | OPRM1 382/4885OPRD1 596/4885OPRK1 369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.